Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
496.160USD
+12.130+2.51%
Close 08-07 16:00（ET）Quotes delayed by 15 min
125.70BMarket Cap
29.18P/E TTM
Forecast
Currency: USD Updated: 2026-08-06The current earnings forecast score of Vertex Pharmaceuticals Inc is 8.00, ranking 58 out of 156 in the Pharmaceuticals industry. The average price target is 492.50, with a high of 604.00 and a low of 330.00.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
557.244
Target Price
+16.41%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Vertex Pharmaceuticals Inc
VRTX
30
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Vertex Pharmaceuticals Inc's expected revenue for the next quarter?
Vertex Pharmaceuticals Inc's expected revenue is 3.40B.
What is Vertex Pharmaceuticals Inc's price target?
Analysts forecast that Vertex Pharmaceuticals Inc's price target is USD 492.50, with the highest forecast at USD 604.00 and the lowest forecast at USD 330.00.
How have Vertex Pharmaceuticals IncVRTX's recent earnings per share performed?
The market expectation was USD 4.34, while Vertex Pharmaceuticals IncVRTX's earnings per share (EPS) for the previous quarter was USD 4.06. EPS for the next quarter is expected at USD 4.80.
What is the analyst rating for Vertex Pharmaceuticals Inc?
Based on the ratings of Vertex Pharmaceuticals Inc's stock from 30 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.